Published in Drug Week, May 6th, 2005
According to the report from the Netherlands, "In-stent restenosis is the major drawback of percutancous coronary interventions, occurring in 10-40% of the patients. Recently, new stents have emerged which are loaded with anti-inflammatory, anti-migratory, anti-proliferative or pro-healing drugs. These drugs are supposed to inhibit inflammation and neointimal growth and subsequently in-stent restenosis."
B.L. van der Hoeven and colleagues of Leiden University continued, "In [our] review article the results of human clinical studies investigating drug-eluting stents are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.